

Multimodality Strategy for Cardiovascular Risk Assessment

Performance in 2 Population-Based Cohorts

BACKGROUND: Current strategies for cardiovascular disease (CVD) risk assessment among adults without known CVD are limited by suboptimal performance and a narrow focus on only atherosclerotic CVD (ASCVD). We hypothesized that a strategy combining promising biomarkers across multiple different testing modalities would improve global and atherosclerotic CVD risk assessment among individuals without known CVD.

METHODS: We included participants from MESA (Multi-Ethnic Study of Atherosclerosis) (n=6621) and the Dallas Heart Study (n=2202) who were free from CVD and underwent measurement of left ventricular hypertrophy by ECG, coronary artery calcium, N-terminal pro B-type natriuretic peptide, high-sensitivity cardiac troponin T, and high-sensitivity C-reactive protein. Associations of test results with the global composite CVD outcome (CVD death, myocardial infarction, stroke, coronary or peripheral revascularization, incident heart failure, or atrial fibrillation) and ASCVD (fatal or nonfatal myocardial infarction or stroke) were assessed over >10 years of follow-up. Multivariable analyses for the primary global CVD end point adjusted for traditional risk factors plus statin use and creatinine (base model).

RESULTS: Each test result was independently associated with global composite CVD events in MESA after adjustment for the components of the base model and the other test results ($P < 0.05$ for each). When the 5 tests were added to the base model, the c-statistic improved from 0.74 to 0.79 ($P = 0.001$), significant integrated discrimination improvement (0.07, 95% confidence interval [CI] 0.06–0.08, $P < 0.001$) and category free net reclassification improvement (0.47; 95% CI, 0.38–0.56; $P = 0.003$) were observed, and the model was well calibrated ($\chi^2 = 12.2$, $P = 0.20$). Using a simple integer score counting the number of abnormal tests, compared with those with a score of 0, global CVD risk was increased among participants with a score of 1 (adjusted hazard ratio, 1.9; 95% CI, 1.4–2.6), 2 (hazard ratio, 3.2; 95% CI, 2.3–4.4), 3 (hazard ratio, 4.7; 95% CI, 3.4–6.5), and ≥ 4 (hazard ratio, 7.5; 95% CI, 5.2–10.6). Findings replicated in the Dallas Health Study were similar for the ASCVD outcome.

CONCLUSIONS: Among adults without known CVD, a novel multimodality testing strategy using left ventricular hypertrophy by ECG, coronary artery calcium, N-terminal pro B-type natriuretic peptide, high-sensitivity cardiac troponin T, and high-sensitivity C-reactive protein significantly improved global CVD and ASCVD risk assessment.

James A. de Lemos, MD
Colby R. Ayers, MS
Benjamin D. Levine, MD
Christopher R. deFilippi, MD

Thomas J. Wang, MD
W. Gregory Hundley, MD
Jarett D. Berry, MD, MS
Stephen L. Seliger, MD
Darren K. McGuire, MD, MHS

Pamela Ouyang, MBBS
Mark H. Drazner, MD, MSc
Matthew Budoff, MD
Philip Greenland, MD
Christie M. Ballantyne, MD
Amit Khera, MD, MSc

Correspondence to: James A. de Lemos, MD, University of Texas Southwestern Medical Center, 5909 Harry Hines Boulevard, E5.7528, Dallas, TX 75390. E-mail james.delemos@utsouthwestern.edu

Sources of Funding, see page 2129

Key Words: biomarker
■ C-reactive protein ■ coronary calcium ■ NT-proBNP ■ risk prediction ■ troponin T

© 2017 American Heart Association, Inc.

Clinical Perspective

What Is New?

- We evaluated a novel strategy for assessment of cardiovascular disease risk among adults without known cardiovascular disease that combined promising biomarkers across multiple different testing modalities, including 12-lead ECG for assessment of left ventricular hypertrophy, coronary artery calcium, N-terminal probrain natriuretic peptide, high-sensitivity cardiac troponin T, and high-sensitivity C-reactive protein.
- Each test result provided incremental information with regard to global cardiovascular disease risk in MESA (Multi-Ethnic Study of Atherosclerosis), and a score containing the 5 results provided robust stratification of global and atherosclerotic cardiovascular disease risk, with findings replicated in the Dallas Heart Study.

What Are the Clinical Implications?

- Our findings support the potential value of a multimodality testing strategy in selected individuals in whom additional risk stratification is desired beyond measurement of traditional atherosclerosis risk factors.
- Additional studies are needed to validate the present findings, determine the optimal approach to implementation, and address direct and indirect cost implications of the additional testing.

Strategies for cardiovascular disease (CVD) risk assessment among adults without known CVD remain largely based on traditional atherosclerosis risk factors.¹ However, these risk prediction equations provide only moderate discrimination of atherosclerotic cardiovascular disease (ASCVD) risk.^{1–3} Moreover, these algorithms typically do not consider risk for additional cardiovascular events, such as heart failure (HF) and atrial fibrillation, which are increasingly important contributors to the overall burden of CVD in the population.^{4,5} A growing body of evidence suggests that preventive interventions such as weight loss, exercise, and more aggressive blood pressure control may favorably impact ASCVD as well as these other highly relevant CVD outcomes.^{6–8}

Previous studies have evaluated individual novel risk markers in an attempt to improve CVD risk prediction and have identified several promising blood- and imaging-based biomarkers.^{9–20} However, for individual biomarkers, even those independently associated with outcomes, the incremental improvement in discrimination and risk classification is typically modest.^{21,22} As a result, investigators have explored combinations of biomarkers as a potential strategy to augment CVD risk prediction, with mixed results.^{23–28} It is important to note that these earlier studies have mostly combined biomarkers

within the same testing modality, such as panels of genetic variants or circulating protein biomarkers, have frequently studied biomarkers with limited specificity for cardiovascular disease, and have included combinations of highly correlated biomarkers.²⁹ To our knowledge, no large studies have combined the most promising individual biomarkers across multiple different testing modalities in an attempt to create a risk prediction tool that augments traditional risk factor strategies.

We hypothesized that a panel combining nonredundant CVD biomarkers across multiple different testing modalities would overcome these limitations and improve CVD risk prediction. The tests prospectively selected included 12-lead ECG for assessment of left ventricular hypertrophy (ECG-LVH),^{30–32} coronary artery calcium (CAC) measurement by computed tomography (CT),^{11–13} and measurement of N-terminal probrain natriuretic peptide (NT-proBNP)^{14–16} high-sensitivity cardiac troponin T (hs-cTnT)^{17–20} and high-sensitivity C-reactive protein (hs-CRP).^{9,10} These tests were selected because they reflect distinct and relevant pathological processes, multiple reports from population-based studies demonstrate independent associations of these measurements with CVD outcomes, and sufficient data exist from which to generate a priori thresholds to define abnormal test results.

METHODS

Study Populations

Study participants were included from examination 1 of the MESA (Multi-Ethnic Study of Atherosclerosis) and phase 1 of the DHS (Dallas Heart Study). Both MESA and DHS are ongoing, multi-ethnic, population-based cohort studies, with methods previously described.^{33,34} Between 2000 and 2002, MESA enrolled 6814 participants 45 to 84 years of age who were free from known CVD. For the present study, we excluded participants missing results from any of the 5 tests, with incomplete follow-up, or missing any of the covariates required for the multivariable analyses, resulting in a final study population of 6621, with complete data for all covariates (Figure 1 in the online-only Data Supplement). A total of 3072 participants from DHS 30 to 65 years of age completed the 3 DHS phase 1 visits between 2000 and 2002, including a detailed in-home survey, laboratory testing, and imaging tests and ECG. For the present study, we excluded participants with prevalent CVD at baseline as well as those missing data on test results or covariates, or with incomplete follow-up, resulting in 2202 participants with complete data for all covariates (Figure 1 in the online-only Data Supplement). MESA was approved by the Institutional Review Boards of the University of Washington and the participating sites, and DHS was approved by the Institutional Review Board of University of Texas Southwestern Medical Center. All participants provided written informed consent.

Data Collection and Variable Definitions

Race/ethnicity, history of CVD, and smoking status were self-reported. Detailed descriptions of variable definitions for

hypertension, diabetes mellitus, hypercholesterolemia, and low high-density lipoprotein cholesterol have been previously described for MESA³³ and DHS³⁵ and are based on conventional clinical definitions.

Multimodality Testing

LVH was determined from standard 12-lead ECGs using the Sokolow-Lyon voltage criteria and defined as present or absent.³⁶ In MESA, CAC scans were performed in duplicate using either electron beam or multidetector CT.³⁷ CAC scores were expressed in Agatston units, and the mean of the 2 scans was used. In DHS, CAC measurements were obtained from electron beam CT scans performed in duplicate 1 to 2 minutes apart as previously described.³⁸ To minimize false-positive CAC classifications because of tissue-associated artifact, a mean Agatston score >10 U was defined as CAC-positive status.³⁸ NT-proBNP and hs-cTnT were measured using the Cobas e601 in MESA and the Elecsys-2010 in DHS^{18,39} (both Roche Diagnostics). hs-CRP was measured using the BNII nephelometer (Dade Behring, Inc.) in MESA⁴⁰ and the Roche/Hitachi 912 System, Tina-quant assay (Roche Diagnostics) in DHS.⁴¹ The following thresholds were prospectively selected to define elevated biomarker levels: NT-proBNP ≥ 100 pg/mL⁴² hs-cTnT ≥ 5 ng/L (the limit of detection),⁴³ and hs-CRP ≥ 3 mg/L.⁴⁴ Values below the limit of blank of the hs-cTnT assay were arbitrarily assigned a level of 1.5 ng/L.

Cohort Follow-Up and End Point Collection

In MESA, participants were contacted by a telephone interviewer at 9- to 12-month intervals to inquire about hospital admissions, CVD diagnoses, and deaths. Medical records and death certificates were requested for all suspected cases, with records obtained in 98% of reported hospitalized CVD events. In DHS, fatal events were ascertained for all subjects using the National Death Index. Deaths were classified as cardiovascular if they included International Statistical Classification of Diseases, 10th Revision codes I00–I99. In the DHS, 2 overlapping approaches were used to capture nonfatal events: (1) a detailed health survey regarding interval cardiovascular events was administered by the Data Coordinating Center during annual calls to study subjects; and (2) for subjects providing informed consent (>90%), quarterly tracking was performed for hospital admissions using the Dallas–Fort Worth Hospital Council Data Initiative Database, which includes all hospital admission data for 70 out of 72 hospitals in the Dallas–Fort Worth area. Primary clinical source documents were collected and reviewed for all suspected nonfatal cardiovascular events in both MESA and DHS and were independently adjudicated by blinded end point committees. Follow-up data for both fatal and nonfatal events was complete through December 31, 2012, in MESA and December 31, 2011, in DHS.

Study End Points

The primary outcome was prospectively defined as time to the first event of a global CVD composite of cardiovascular death, myocardial infarction, stroke, coronary or peripheral revascularization >3 months after enrollment, incident HF, or atrial fibrillation. The major secondary end point was hard ASCVD events, including fatal or nonfatal myocardial infarction

and fatal or nonfatal stroke. Tertiary end points included coronary heart disease (CHD) (fatal or nonfatal myocardial infarction), incident HF, all-cause mortality, and CVD mortality. The tertiary end points were evaluated with univariable analyses only in DHS because of the small numbers of these events, which precluded multivariable adjustment. A blanking period of 3 months for revascularization events was used to account for any influence of the study visit or CAC measurement on revascularization decisions.

Statistical Methods

All analyses were performed separately in MESA and DHS. The analysis strategy considered the test results as both continuous and categorical variables. In the continuous variable analyses, CAC, NT-proBNP, hs-cTnT, and hs-CRP were modeled as natural log-transformed continuous variables, with a value of 1 added to CAC because of the large numbers of zero values, and ECG-LVH was modeled as a dichotomous variable. In the categorical analyses, all variables were modeled as dichotomous variables using the prespecified cutpoints described previously. Associations of test results with study outcomes were assessed using unadjusted and adjusted Cox proportional hazards models, with all covariates determined a priori. The base model included traditional risk factors: age, sex, race/ethnicity, smoking status, diabetes mellitus, total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, blood pressure medications, and statin use. For the primary global CVD outcome, serum creatinine was included in the base model, and for the HF outcome, both creatinine and body mass index were included in the base model.^{45,46} The first multivariable model added individual test results to the base model, and the second model added all 5 of the test results to the base model. Assumptions for the Cox proportional hazards models were verified by Schoenfeld residuals.

Improvement in discrimination and reclassification for the primary global CVD outcome and the secondary ASCVD outcome was assessed by comparing the base model with the model that included the base model plus the 5 screening tests. Discrimination was assessed using Harrell's *c*-statistic, with confidence intervals determined by a jackknife resampling method. Improvement in the *c*-statistic was determined using bootstrap resampling. Integrated discrimination improvement, reflecting the difference in discrimination slopes between models with and without the markers, was determined using the failure probabilities from the Cox-proportional hazards models.⁴⁷ Category-free net reclassification improvement was performed for all end points according to methods described by Pencina et al.⁴⁸ Calibration of the global CVD and ASCVD models was assessed by the modified Hosmer–Lemeshow test for time-to-event data. For the primary analyses, coefficients were determined separately for each model in MESA and DHS. Sensitivity analyses were performed in which the full multivariable models with continuous biomarker coefficients from MESA were applied directly to the DHS cohort.

To facilitate clinical application of the multimodality strategy, a simple integer score counting the number of abnormal screening test results was created, with values ranging from 0 to 5. In MESA scores of 4 to 5 were collapsed, and in DHS scores of 3 to 5 were collapsed because of the small numbers of participants in the highest risk categories. Cumulative

rates of the primary composite outcome were determined and displayed using the Nelson–Aalen failure estimator, with groups compared with the log-rank test. Multivariable adjusted Cox-proportional hazards analyses were performed, adjusting for the variables contained in the base model. A similar approach using the same integer score was used for secondary and tertiary end points. Unadjusted stratified analyses were performed in subgroups defined by sex, younger age (men <55, women <65), race/ethnicity (black, white, Hispanic), and estimated 10-year ASCVD risk <7.5% using the pooled cohort equations.¹

Statistical analyses were conducted using SAS version 9.4 (SAS Institute, Inc.), and all *P* values are 2-sided with an alpha of 0.05. Published SAS macros were used to assess measures of fit.⁴⁹

RESULTS

Participant characteristics are detailed in Table 1. Median age at enrollment was 62 years in MESA and 44 years in DHS. In MESA, over a median 11 years of follow-up, 1026 global CVD events occurred, including 486 ASCVD events. In the DHS, over a median follow-up period of 10.3 years, 179 global CVD events occurred, including 96 ASCVD events. The prevalence of abnormal results on the 5 tests in MESA and DHS is shown in Table 1 and ranged from 9% for ECG-LVH (in both cohorts) to 45% for hs-CRP (in DHS). The individual test results were not highly correlated in either MESA or DHS (Tables I and II in the online-only Data Supplement).

Associations of Test Results With Outcomes

In MESA, each of the 5 tests was associated with the primary global CVD outcome after adjustment for traditional risk factors and the other test results, with results consistent whether the tests were considered as continuous variables or using the prospective dichotomous cutpoints (Table 2). Findings replicated in DHS, with the exception that hs-CRP was not independently associated with global CVD after multivariable adjustment (Table 2). Associations of the test results with the secondary composite ASCVD outcomes are shown in Table 3. In MESA, each of the test results except hs-CRP was independently associated with ASCVD. In DHS, associations of hs-CRP and hs-cTnT with ASCVD were attenuated after adjustment for risk factors (Table 3). Associations of the screening tests with tertiary end points were largely concordant in MESA and DHS, with variation seen depending on which end point was evaluated (Tables III–VI in the online-only Data Supplement). CAC was most strongly associated with coronary heart disease events, followed by NT-proBNP and hs-cTnT, with no association seen for ECG-LVH or hs-CRP (Table III in the online-only Data Supplement). All 5 test results were independently associated with incident HF, with the largest hazards seen for NT-proBNP, ECG-LVH, and hs-cTnT. NT-proBNP demonstrated the larg-

Table 1. Baseline Characteristics

Variable	Multi-Ethnic Study of Atherosclerosis	Dallas Heart Study
N	6621	2202
Age, y	62 [53–70]	44 [37–52]
Male, %	47	44
Race/ethnicity, %		
White	38	34
Black	27	47
Hispanic	22	16
Asian/other	12	2
Body mass index	27.6 [24.6–31.2]	28.2 [24.6–32.4]
Hypertension, %	45	31
Medication for hypertension, %	37	19
Systolic blood pressure	124 [112–140]	121 [112–133]
Diastolic blood pressure	72 [65–79]	77 [71–84]
Diabetes mellitus, %	13	9
Current smoker, %	13	27
Hypercholesterolemia, %	37	13
Statin medication, %	15	6
Lipids		
Total cholesterol	192 [170–215]	180 [157–205]
LDL cholesterol	116 [96–136]	106 [84–129]
HDL cholesterol	48 [40–59]	48 [40–58]
Triglycerides	111 [78–161]	97 [69–146]
Test results		
ECG-LVH, %	9	9
Coronary artery calcium score, Agatston U	0 [0–86.5]	0.5 [0–4.3]
Coronary artery calcium score >10 U, %	42	19
NT-proBNP, pg/mL	53.0 [24.0–107.7]	27.4 [12.7–56.0]
NT-proBNP ≥100 pg/mL, %	27	11
Hs-cTnT, ng/L	4.4 [3.0–7.5]	1.5 [1.5–1.5]
Hs-cTnT ≥5 ng/L, %	44	14
Hs-CRP, mg/L	1.9 [0.8–4.2]	2.7 [1.1–6.2]
Hs-CRP ≥3 mg/L, %	36	45
End points, n (%)		
Global cardiovascular disease	1026 (15.5)	179 (8.1)
Atherosclerotic cardiovascular disease	486 (7.3)	96 (4.4)

(Continued)

Table 1. Continued

Variable	Multi-Ethnic Study of Atherosclerosis	Dallas Heart Study
Coronary heart disease	314 (4.7)	61 (2.8)
Congestive heart failure	252 (3.8)	28 (1.3)
All-cause death	806 (12.2)	94 (4.3)
Cardiovascular death	183 (2.8)	46 (2.1)

HDL indicates high-density lipoprotein; Hs-CRP, high-sensitivity C-reactive protein; Hs-cTnT, high-sensitivity cardiac troponin T; LDL, low-density lipoprotein; LVH, left ventricular hypertrophy; and NT-proBNP, N-terminal prohormone of B-type natriuretic peptide.

Continuous variables are presented as median [interquartile range].

est hazard ratio for fatal outcomes, followed by hs-cTnT. ECG-LVH associated with CVD mortality but not all-cause mortality (Tables III–VI in the online-only Data Supplement).

Evaluation of Risk Prediction Metrics

Addition of the 5 tests to the base model improved the c-statistic for global and ASCVD in both DHS and MESA and for each of the tertiary end points in MESA ($P < 0.01$ for each; Table 4), with the largest increase in c-statistic seen for the global CVD and HF end points. Addition of

the test results also resulted in significant category-free net reclassification improvement and integrated discrimination improvement for the global CVD end point in both MESA and DHS (Table 4). Models including the 5 tests were well calibrated in both MESA and DHS for both global and ASCVD end points (Figures II and III in the online-only Data Supplement). In exploratory analyses focusing only on the ASCVD end point in MESA, the largest improvement in risk prediction metrics was observed when CAC was added to the base model, with modest but significant increments beyond CAC in the c-statistic, net reclassification improvement, and integrated discrimination improvement observed for the addition of NT-proBNP and hs-cTnT but not for the addition of ECG-LVH or hs-CRP (Table VII in the online-only Data Supplement).

In sensitivity analyses, the MESA base models and models including all 5 test results were applied directly to DHS using coefficients for all variables derived from MESA. In these analyses, both base and fully adjusted models had lower c-statistics than the models in which the coefficients were derived in the DHS dataset. However, improvements in the c-statistic, net reclassification improvement, and integrated discrimination improvement were similar using the 2 modeling strategies (Table VIII in the online-only Data Supplement). Calibration remained adequate in DHS when the MESA models were directly ap-

Table 2. Association of Test Results With the Primary Composite Global Cardiovascular Disease Outcome

Variable	Unadjusted Hazard Ratio (95% CI)		Model 1 Hazard Ratio (95% CI)*		Model 2 Hazard Ratio (95% CI)†	
	Multi-Ethnic Study of Atherosclerosis	Dallas Heart Study	Multi-Ethnic Study of Atherosclerosis	Dallas Heart Study	Multi-Ethnic Study of Atherosclerosis	Dallas Heart Study
Continuous test results						
ECG-LVH‡	1.84 (1.55–2.19)	2.60 (1.78–3.79)	1.39 (1.17–1.67)	1.73 (1.16–2.57)	1.24 (1.04–1.49)	1.72 (1.15–2.57)
Ln (CAC+1)	2.14 (2.02–2.28)	1.96 (1.76–2.12)	1.62 (1.51–1.74)	1.31 (1.14–1.50)	1.55 (1.44–1.66)	1.31 (1.14–1.50)
Ln (NT-proBNP)	1.88 (1.76–2.01)	1.67 (1.44–1.94)	1.64 (1.52–1.77)	1.27 (1.07–1.50)	1.48 (1.37–1.60)	1.19 (1.01–1.41)
Ln (hs-cTnT)	1.74 (1.67–1.83)	1.74 (1.58–1.91)	1.36 (1.28–1.45)	1.21 (1.05–1.39)	1.22 (1.14–1.31)	1.17 (1.01–1.35)
Ln (hs-CRP)	1.20 (1.13–1.28)	1.22 (1.05–1.43)	1.18 (1.10–1.26)	0.98 (0.83–1.16)	1.16 (1.08–1.24)	0.97 (0.82–1.15)
Categorical test results						
ECG-LVH‡	1.84 (1.55–2.19)	2.60 (1.78–3.79)	1.39 (1.17–1.67)	1.73 (1.16–2.57)	1.34 (1.12–1.61)	1.71 (1.15–2.55)
CAC >10 U	3.86 (3.37–4.41)	4.95 (3.69–6.64)	2.13 (1.84–2.47)	1.78 (1.26–2.52)	2.05 (1.76–2.38)	1.81 (1.28–2.55)
NT-proBNP ≥100 pg/mL	2.62 (2.31–2.96)	3.81 (2.76–5.25)	1.84 (1.60–2.12)	2.04 (1.40–2.98)	1.70 (1.48–1.96)	1.88 (1.29–2.75)
hs-cTnT ≥5 ng/L	3.06 (2.69–3.49)	4.05 (2.99–5.49)	1.49 (1.28–1.73)	1.53 (1.06–2.19)	1.38 (1.19–1.60)	1.46 (1.01–2.11)
hs-CRP ≥3 mg/L	1.46 (1.29–1.65)	1.52 (1.13–2.04)	1.45 (1.27–1.65)	1.10 (0.80–1.51)	1.39 (1.22–1.59)	1.06 (0.78–1.46)

CAC indicates coronary artery calcium score; HDL, high-density lipoprotein; hs-cTnT, high-sensitivity cardiac troponin T; LVH, left ventricular hypertrophy; and NT-proBNP, N-terminal prohormone of B-type natriuretic peptide.

*Model 1 is adjusted for age, sex, race, smoking status, diabetes mellitus, total cholesterol, HDL cholesterol, systolic blood pressure and blood pressure medications, statin medications, and creatinine.

†Model 2 includes the components of model 1 and all 5 test results. The hazard ratio for continuous test results reflects a 1 standard deviation change in Ln of the test result. N=1026 end points in the Multi-Ethnic Study of Atherosclerosis and N=179 in the Dallas Heart Study.

‡ECG-LVH was treated as a categorical variable in both analyses. Coefficients were determined separately for each model.

Table 3. Association of Test Results With the Composite Atherosclerotic Cardiovascular Disease Outcome

Variable	Unadjusted Hazard Ratio (95% CI)		Model 1 Hazard Ratio (95% CI)*		Model 2 Hazard Ratio (95% CI)†	
	Multi-Ethnic Study of Atherosclerosis	Dallas Heart Study	Multi-Ethnic Study of Atherosclerosis	Dallas Heart Study	Multi-Ethnic Study of Atherosclerosis	Dallas Heart Study
Continuous test results						
ECG-LVH‡	1.71 (1.33–2.21)	2.76 (1.67–4.56)	1.24 (0.95–1.61)	1.83 (1.07–3.12)	1.14 (0.87–1.48)	1.84 (1.08–3.14)
Ln (CAC+1)	2.04 (1.87–2.22)	2.17 (1.88–2.50)	1.56 (1.41–1.73)	1.43 (1.20–1.72)	1.49 (1.34–1.65)	1.43 (1.19–1.72)
Ln (NT-proBNP)	1.73 (1.62–1.85)	1.56 (1.27–1.92)	1.45 (1.30–1.61)	1.25 (1.01–1.55)	1.29 (1.15–1.43)	1.18 (0.95–1.47)
Ln (hs-cTnT)	1.73 (1.62–1.85)	1.74 (1.53–1.97)	1.37 (1.25–1.49)	1.16 (0.98–1.38)	1.23 (1.12–1.35)	1.11 (0.93–1.34)
Ln (hs-CRP)	1.17 (1.08–1.28)	1.19 (0.97–1.47)	1.09 (0.99–1.21)	0.97 (0.77–1.22)	1.07 (0.97–1.17)	0.93 (0.74–1.18)
Categorical test results						
ECG-LVH‡	1.71 (1.33–2.21)	2.45 (1.49–4.02)	1.24 (0.95–1.61)	1.69 (0.99–2.87)	1.19 (0.92–1.55)	1.88 (1.10–3.20)
CAC >10 U	3.87 (3.18–4.72)	7.27 (4.87–10.85)	2.17 (1.74–2.70)	2.31 (1.44–3.70)	2.09 (1.67–2.60)	2.31 (1.44–3.71)
NT-proBNP ≥100 pg/mL	2.44 (2.04–2.92)	3.22 (2.10–4.92)	1.69 (1.35–2.11)	2.25 (1.38–3.68)	1.55 (1.26–1.91)	1.99 (1.19–3.32)
hs-cTnT ≥5 ng/L	2.78 (2.31–3.36)	4.20 (2.87–6.17)	1.40 (1.13–1.74)	1.43 (0.91–2.25)	1.29 (1.04–1.59)	1.23 (0.75–2.02)
hs-CRP ≥3 mg/L	1.38 (1.16–1.65)	1.54 (1.05–2.25)	1.24 (1.02–1.50)	1.12 (0.74–1.69)	1.19 (0.98–1.44)	1.10 (0.72–1.70)

CAC indicates coronary artery calcium score; HDL, high-density lipoprotein; hs-cTnT, high-sensitivity cardiac troponin T; LVH, left ventricular hypertrophy; MESA, Multi-Ethnic Study of Atherosclerosis; and NT-proBNP, N-terminal prohormone of B-type natriuretic peptide.

*Model 1 is adjusted for age, sex, race, smoking status, diabetes mellitus, total cholesterol, HDL cholesterol, systolic blood pressure and blood pressure medications, and statin use.

†Model 2 includes the components of model 1 and all 5 test results. The hazard ratio for continuous test results reflects a 1 standard deviation change in the Ln of the test result. N=486 events in the Multi-Ethnic Study of Atherosclerosis and N=96 in the Dallas Heart Study.

‡ECG-LVH was treated as a categorical variable in both analyses. Coefficients were determined separately for each model.

plied (Figure IV in the online-only Data Supplement) but as expected was worse compared with the models in which coefficients were derived in DHS.

Multimodality Risk Score

Participants were assigned 1 point for each abnormal test result, yielding an integer score ranging from 0 to 5. The proportion of individuals with scores of 0, 1, 2, 3, or ≥4 was 20%, 30%, 27%, 17%, and 6% in MESA and the proportion with scores of 0, 1, 2, and ≥3 in DHS was 35%, 42%, 17%, and 7%, respectively (Figure V in the online-only Data Supplement). A >20-fold gradient of risk for both global CVD and ASCVD was observed across higher scores in both MESA and DHS (Figure 1). In MESA, participants with scores ≥2 comprised <50% of the cohort but accounted for 79% of the events. In the younger DHS population, participants with a score ≥2 comprised 24% of the cohort but accounted for 58% of events (Figure V in the online-only Data Supplement). In both MESA and DHS, consistent graded associations with global CVD and ASCVD risk were seen with increasing scores across sex and race/ethnic subgroups and in younger and lower risk individuals (Figure 2, Figure VI in the online-only Data Supplement).

As expected, higher scores were associated with a greater burden of traditional risk factors (Tables IX and X in the online-only Data Supplement). However, in multi-variable analyses accounting for traditional risk factors, compared with those with a score of 0 in MESA, CVD risk increased among participants with a score of 1 (hazard ratio [HR], 1.9; 95% confidence interval [CI], 1.4–2.6), 2 (HR, 3.2; 95% CI 2.3–4.4), 3 (HR, 4.7; 95% CI 3.4–6.5), and ≥4 (HR, 7.5, 95% CI, 5.2–10.6) (Figure 3). Similar graded associations across higher scores were seen for the secondary ASCVD end point and with tertiary end points, with findings most robust for incident HF (Figure 3). In the DHS, higher scores were also associated with global CVD, ASCVD, and all-cause mortality in the fully adjusted models (Figure VII in the online-only Data Supplement).

DISCUSSION

In the present study, we combined 5 promising tests for cardiovascular risk stratification among adults without known CVD: the 12-lead ECG to assess LVH, CAC scanning, and measurement of NT-proBNP, hs-cTnT, and hs-CRP. Although this combination of tests captures multiple

Table 4. Change in Risk Prediction Metrics With Additional of Test Results to Base Models

Variable	Multi-Ethnic Study of Atherosclerosis				Dallas Heart Study			
	C-Statistic Base Model*	C-Statistic Base Model + Test Results	Category-Free Net Reclassification Improvement	Integrated Discrimination Improvement	C-Statistic Base Model*	C-Statistic Base Model + Test Results	Category-Free Net Reclassification Improvement	Integrated Discrimination Improvement
Global cardiovascular disease	0.743	0.786†	0.473 (0.383–0.563)	0.073 (0.063–0.083)	0.832	0.850‡	0.261 (0.052–0.470)	0.024 (0.008–0.040)
Atherosclerotic cardiovascular disease	0.748	0.779†	0.394 (0.275–0.512)	0.042 (0.032–0.052)	0.859	0.873‡	0.355 (0.129–0.581)	0.021 (0.001–0.041)
Coronary heart disease	0.749	0.794†	0.498 (0.357–0.638)	0.043 (0.031–0.055)	0.865	0.889‡	0.585 (0.294–0.877)	0.058 (0.023–0.093)
Heart failure	0.786	0.847†	0.549 (0.407–0.692)	0.086 (0.064–0.108)	0.840	0.871§	0.719 (0.381–0.989)	0.130 (0.042–0.218)
All-cause mortality	0.746	0.789†	0.315 (0.199–0.431)	0.038 (0.030–0.046)	0.817	0.829	0.061 (–0.516 to 0.638)	0.030 (0.005–0.055)
Cardiovascular mortality	0.822	0.840‡	0.438 (0.185–0.691)	0.050 (0.032–0.068)	0.840	0.858	0.308 (–0.045 to 0.662)	0.012 (–0.010 to 0.034)

*Base model includes variables in the pooled cohort equations plus statin therapy. Global cardiovascular disease models also include creatinine, and heart failure models also include body mass index and creatinine. Coefficients were determined separately for each model.

† $P < 0.001$ versus base model.

‡ $P < 0.01$ versus base model.

§ $P < 0.05$ versus base model.

well-defined cardiac pathological processes, including cardiac hypertrophy, coronary atherosclerosis, neurohormonal activation, cardiomyocyte injury, and inflammation, to our knowledge they have not been considered together previously. Each test provided nonredundant incremental information to traditional risk factors, and when the test results were combined in a simple integer score, a >20-fold gradient in risk for the primary global CVD outcome was seen across the range of scores after >10 years of follow-up. The findings were consistent among women, ethnic minorities, younger individuals, and those at low predicted risk for ASCVD. Results were robust to multivariable adjustment and across different CVD end points, and replicated in 2 distinct cohorts with different age ranges and race/ethnic distributions. Discrimination and risk classification were improved for both global and ASCVD outcomes, and models incorporating the screening test results were generally well calibrated. These findings provide strong evidence that a simple strategy including the most promising biomarkers from several different testing modalities substantially improves CVD risk prediction among individuals without known CVD.

CVD risk stratification has traditionally been focused on predicting only CHD events. More recently, in concert with changes in prevention guidelines,^{1,50} the focus of CVD risk prediction has expanded to include stroke. It is notable that although rates of myocardial infarction and

stroke have been steadily declining,⁵¹ the prevalence of HF is projected to increase by 25% over the next 20 years.⁴ Among middle-age adults, the 10-year risk of incident HF is $\approx 10\%$,⁵² with lifetime risks of 30% to 40%.⁵³ Tools to predict incident HF may allow targeted therapies to prevent its development, which could have important public health implications given its associated morbidity and mortality. To date only a single global CVD risk model has been developed that considers ASCVD and HF together⁵⁴ and differs from our approach because it only contained traditional CHD risk factors as covariates and did not include atrial fibrillation as part of the global CVD outcome.⁵⁴ Like HF, atrial fibrillation is rapidly increasing in prevalence, is difficult to treat once present, and carries substantial costs and morbidity.^{5,55} A focus on global CVD risk prediction, incorporating end points of HF and atrial fibrillation as was done in the present study, is likely to become increasingly important. It is important to note that global CVD risk assessment should be considered as a complement and not a replacement for cause-specific risk estimation (ie, for ASCVD).

Although the individual biomarkers were each associated with the primary composite global CVD end point, they differed in their relative associations with secondary and tertiary CVD end points, as would be expected on the basis of the pathological processes captured by each biomarker.^{11,15,18,31,39} For example, CAC demonstrated the largest HR for ASCVD and CHD events,




Figure 1. Kaplan Meir estimates of the rates of the composite global cardiovascular disease (CVD) and atherosclerotic cardiovascular disease (ASCVD) outcomes stratified by the number of abnormal test results.

A, Global CVD outcome in the Multi-Ethnic Study of Atherosclerosis. **B,** ASCVD outcome in the Multi-Ethnic Study of Atherosclerosis. **C,** Global CVD outcome in the Dallas Heart Study. **D,** ASCVD outcome in the Dallas Heart Study.

whereas NT-proBNP and hs-cTnT were associated with the highest hazards for all-cause and CVD mortality and HF. It is notable that although NT-proBNP and hs-cTnT were included to enhance global CVD risk prediction, they also provided independent prognostic value for ASCVD and CHD in MESA. While hs-CRP provided modest incremental information for the global CVD and HF end points, this biomarker generally demonstrated the weakest and least consistent associations across the portfolio of end points. Further, the multimodality strategy provided robust discrimination and reclassification for ASCVD and global CVD events. Thus, this strategy may contribute to more accurate identification of appropriate candidates for ASCVD preventive therapies while capturing risk for broader CVD events.

Several limitations of the present study merit consideration. First, this study was not designed to determine the optimal number or combination of the screening

tests for risk stratification purposes. The number of potential combinations of the 5 tests is 120, and each potential combination could be considered for multiple end points. Second, the number of end points in the DHS was too low to perform multivariable adjustment for the tertiary end points. However, the adjusted results for the primary and secondary outcomes demonstrated consistent results compared with MESA, as did unadjusted analyses for the tertiary end points. Last, we acknowledge that comparing strength of association between the different tests presents challenges and can be influenced by the incidence of the different end points and distributions of the test results in the study cohorts.

The goal of our study was to evaluate prospectively a multimodality risk prediction strategy and replicate the findings in a second population-based dataset. We did not design our primary analyses to validate the MESA




Figure 2. Unadjusted association between the number of abnormal test results and the composite global cardiovascular disease (CVD) and atherosclerotic cardiovascular disease (ASCVD) outcomes in selected subgroups in the Multi-Ethnic Study of Atherosclerosis.

Hazard ratios (HR) represent comparisons versus participants with zero abnormal test results. No significant interactions were seen across subgroups ($P > 0.05$ for each). Younger age is defined as < 55 years of age in men and < 65 years of age in women. Low estimated risk is defined as 10-year estimated ASCVD risk $< 7.5\%$ using the pooled cohort equations.

multivariable models in DHS but rather to determine whether the scientific approach replicated in a second dataset. We did perform sensitivity analyses in which the MESA models were applied directly to the DHS. Although the overall performance of the models was modestly impacted (as would be expected), the improvement in model performance with the addition of the 5 tests was generally similar to the primary analysis approach in which the coefficients were derived in the DHS. The models from MESA were also less well calibrated when applied to DHS, particularly for the ASCVD end point, although calibration remained adequate. Additional prospective validation is required before the multivariable models can be considered for clinical application.

Clinical Implications

Current consensus recommendations support only selective additional testing beyond traditional cardiovascular risk factors.^{1,22} However, combinations of tests were not assessed in these guidelines, and the gradients of risk seen with the individual tests considered in these documents were not as large in magnitude as those

seen with the multimodality risk score in the current study. Our robust findings support the potential value of a multimodality testing strategy using these markers in selected individuals in whom additional risk stratification is desired.

The multimodality testing strategy may help to individualize and more efficiently target cardiovascular prevention efforts in primary care. Although current prevention guidelines recommend a risk-based approach only when implementing statin and aspirin therapy, the role for targeting therapy on the basis of risk in primary prevention is likely to expand in the future. For example, the SPRINT (Systolic Blood Pressure Intervention Trial) demonstrated that lowering blood pressure below currently recommended targets was associated with reduced rates of HF and all-cause mortality,⁸ end points that were predicted well by the tests studied here. The favorable effects of more aggressive blood pressure lowering in SPRINT were balanced by side effects and some safety concerns, and the resource implications of broad implementation of lower blood pressure targets would be substantial. In addition, a novel agent for the management of diabetes mellitus, empagliflozin,




Figure 3. Multivariable-adjusted association between the number of abnormal test results and cardiovascular end points in the Multi-Ethnic Study of Atherosclerosis.

Hazard ratios (HR) represent comparisons versus participants with zero abnormal test results. All models were adjusted for age, sex, race, smoking status, diabetes mellitus, total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure and blood pressure medications, and statin medications. The global CVD and mortality models were also adjusted for serum creatinine, and the heart failure models were additionally adjusted for body mass index and creatinine. ASCVD indicates atherosclerotic CVD; CHD, coronary heart disease; CHF, congestive heart failure; CV, cardiovascular; and CVD, cardiovascular disease.

recently demonstrated a 38% reduction in death from cardiovascular causes and 35% reduction in HF, with lesser impact on ASCVD end points.⁵⁶ Targeting empagliflozin to patients at highest risk for death and HF events may be a prudent strategy given the high cost of the drug. Thus, an individualized, risk-based approach using traditional risk factors plus biomarkers may be appropriate when determining blood pressure targets or implementing newer therapies that favorably impact CVD end points beyond ASCVD.

The multimodality strategy could also facilitate targeting of global and disease-specific CVD prevention efforts as population health care becomes an increasing focus of healthcare delivery. For example, among individuals with a risk score of 0, global CVD risk was extremely low in both MESA and DHS (<3% over 10 years in each study), and this large group of individuals could be managed with a low-intensity/low-cost approach. In contrast, higher scores clearly captured risk not recognized with traditional risk factor algorithms, as consistent results were seen even among individuals estimated to be at low risk with the pooled cohort equations. Individuals

with scores ≥ 2 , for example, represented <50% of MESA participants and 25% of the younger DHS cohort, yet accounted for 79% and 58% of global CVD events, respectively. A tailored and incrementally more intensive approach to global CVD risk reduction would be appropriate for individuals with a greater number of abnormal test results. For example, higher risk individuals could be referred to lifestyle intervention programs, focusing on improving low fitness and obesity, which are important contributors to multiple components of the global CVD end point. Triage for cardiovascular specialist evaluation may be considered for the highest risk individuals, a strategy recently evaluated for a biomarker screening program in primary care with promising preliminary results.⁵⁷ Although each of the 5 tests is available clinically and thus measurement is currently feasible, larger studies will be needed to validate the present findings and elucidate the optimal strategy for clinical implementation. Moreover, additional consideration of costs, both those directly related to the tests and those engendered by abnormal test results, would be necessary before implementation.

CONCLUSION

A novel multimodality CVD risk assessment strategy using the nonredundant markers of ECG-LVH, CAC, NT-proBNP, hs-cTnT, and hs-CRP substantially improved global and atherosclerotic CVD risk stratification among individuals from the general population free from CVD at study entry. Additional study of preventive strategies incorporating these complementary tests is indicated.

ACKNOWLEDGMENTS

The authors thank the other investigators as well as the staff and participants of the Multi-Ethnic Study of Atherosclerosis and Dallas Heart Study studies for their valuable contributions. A full list of participating Multi-Ethnic Study of Atherosclerosis investigators and institutions can be found at <http://www.mesa-nhlbi.org>.

SOURCES OF FUNDING

This study was funded by research grant CA03801 awarded to Dr de Lemos from the National Space Biomedical Research Institute. The Multi-Ethnic Study of Atherosclerosis was supported by R01 HL071739 and contracts N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, and N01-HC-95169 from the National Heart, Lung, and Blood Institute. The Dallas Heart Study was funded by a grant from the Donald W. Reynolds Foundation. Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under award number UL1TR001105 to the University of Texas Southwestern Medical Center. Biomarker measurements were supported by investigator-initiated grants to Drs de Lemos and DeFilippi from Roche Diagnostics. Roche Diagnostics had no role in the design and conduct of the study and did not participate in analysis or interpretation of the data. They were not provided a summary report of the data and have not reviewed this submission.

DISCLOSURES

Dr de Lemos has received grant support from Roche Diagnostics and Abbott Diagnostics, and consulting income from Roche Diagnostics, Abbott Diagnostics, Ortho Clinical Diagnostics, Prevencio, Diadexus, Siemen's Healthcare, Radiometer, and Amgen. Dr DeFilippi has received research support from Roche Diagnostics, Abbott Diagnostics, and Critical Diagnostics, and consulting fees or honoraria from Roche Diagnostics, Siemens Healthcare Diagnostics, Thermo-Fisher, and Radiometer. Dr Wang has received consulting fees from Ultragenyx. Dr Seliger has received grant support from Roche Diagnostics. Dr Budoff has received grant support from General Electric. Dr Ballantyne has received grant support from Roche Diagnostics and Abbott Diagnostics, and has a provision patent (filed by Baylor College of Medicine and Roche) for the use of biomarkers to improve the prediction of heart failure.

AFFILIATIONS

From Departments of Medicine (J.A.d.L., B.D.L., J.P.B., D.K.M., M.H.D., A.K.) and Clinical Sciences (C.R.A., J.D.B., D.K.M.), University of Texas Southwestern Medical Center, Dallas; Institute for Exercise and Environmental Medicine, Texas Health Presbyterian, Dallas (B.D.L.); Inova Heart and Vascular Institute, Fall Church, VA (C.R.d.); Department of Medicine, Vanderbilt University Medical Center, Nashville, TN (T.J.W.); Departments of Medicine and Radiological Sciences, Wake Forest Health Sciences, Winston-Salem, NC (W.G.H.); Department of Medicine, University of Maryland School of Medicine, Baltimore (S.L.S.); The Johns Hopkins University School of Medicine, Baltimore, MD (P.O.); Los Angeles Biomedical Research Institute, CA (M.B.); Departments of Preventive Medicine and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (P.G.); and Baylor College of Medicine, Houston, TX (G.M.B.).

FOOTNOTES

Received January 7, 2017; accepted March 3, 2017.

The online-only Data Supplement is available with this article at <http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIRCULATIONAHA.117.027272/-/DC1>.

Guest Editor for this article was Paul M. Ridker, MD. *Circulation* is available at <http://circ.ahajournals.org>.

REFERENCES

- Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, Greenland P, Lackland DT, Levy D, O'Donnell CJ, Robinson JG, Schwartz JS, Shero ST, Smith SC Jr, Sorlie P, Stone NJ, Wilson PW, Jordan HS, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2014;129(25 Suppl 2):S49–S73. doi: 10.1161/01.cir.0000437741.48606.98.
- Ridker PM, Cook NR. Statins: new American guidelines for prevention of cardiovascular disease. *Lancet*. 2013;382:1762–1765. doi: 10.1016/S0140-6736(13)62388-0.
- Muntner P, Colantonio LD, Cushman M, Goff DC Jr, Howard G, Howard VJ, Kissela B, Levitan EB, Lloyd-Jones DM, Safford MM. Validation of the atherosclerotic cardiovascular disease pooled cohort risk equations. *JAMA*. 2014;311:1406–1415. doi: 10.1001/jama.2014.2630.
- Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, Finkelstein EA, Hong Y, Johnston SC, Khara A, Lloyd-Jones DM, Nelson SA, Nichol G, Orenstein D, Wilson PW, Woo YJ; American Heart Association Advocacy Coordinating Committee; Stroke Council; Council on Cardiovascular Radiology and Intervention; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Council on Arteriosclerosis; Thrombosis and Vascular Biology; Council on Cardiopulmonary; Critical Care; Perioperative and Resuscitation; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease; Council on Cardiovascular Surgery and Anesthesia, and Interdisciplinary Council on Quality of Care and Outcomes Research. Forecasting the future of cardiovascular disease in the United States: a policy statement from the

- American Heart Association. *Circulation*. 2011;123:933–944. doi: 10.1161/CIR.0b013e31820a55f5.
5. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, Gillum RF, Kim YH, McAnulty JH Jr, Zheng ZJ, Forouzanfar MH, Naghavi M, Mensah GA, Ezzati M, Murray CJ. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. *Circulation*. 2014;129:837–847. doi: 10.1161/CIRCULATIONAHA.113.005119.
 6. Miller JD, Aronis KN, Chrispin J, Patil KD, Marine JE, Martin SS, Blaha MJ, Blumenthal RS, Calkins H. Obesity, exercise, obstructive sleep apnea, and modifiable atherosclerotic cardiovascular disease risk factors in atrial fibrillation. *J Am Coll Cardiol*. 2015;66:2899–2906. doi: 10.1016/j.jacc.2015.10.047.
 7. deFilippi CR, de Lemos JA, Tkaczuk AT, Christenson RH, Carnethon MR, Siscovick DS, Gottdiener JS, Seliger SL. Physical activity, change in biomarkers of myocardial stress and injury, and subsequent heart failure risk in older adults. *J Am Coll Cardiol*. 2012;60:2539–2547. doi: 10.1016/j.jacc.2012.08.1006.
 8. Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A randomized trial of intensive versus standard blood-pressure control. *N Engl J Med*. 2015;373:2103–2116.
 9. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. *N Engl J Med*. 2000;342:836–843. doi: 10.1056/NEJM200003233421202.
 10. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. *JAMA*. 2001;285:2481–2485.
 11. Detrano R, Guerci AD, Carr JJ, Bild DE, Burke G, Folsom AR, Liu K, Shea S, Szklo M, Bluemke DA, O'Leary DH, Tracy R, Watson K, Wong ND, Kronmal RA. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. *N Engl J Med*. 2008;358:1336–1345. doi: 10.1056/NEJMoa072100.
 12. Erbel R, Möhlenkamp S, Moebus S, Schmermund A, Lehmann N, Stang A, Dragano N, Grönemeyer D, Seibel R, Kälsch H, Bröcker-Preuss M, Mann K, Siegrist J, Jöckel KH; Heinz Nixdorf Recall Study Investigative Group. Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall study. *J Am Coll Cardiol*. 2010;56:1397–1406. doi: 10.1016/j.jacc.2010.06.030.
 13. Polonsky TS, McClelland RL, Jorgensen NW, Bild DE, Burke GL, Guerci AD, Greenland P. Coronary artery calcium score and risk classification for coronary heart disease prediction. *JAMA*. 2010;303:1610–1616. doi: 10.1001/jama.2010.461.
 14. Everett BM, Berger JS, Manson JE, Ridker PM, Cook NR. B-type natriuretic peptides improve cardiovascular disease risk prediction in a cohort of women. *J Am Coll Cardiol*. 2014;64:1789–1797. doi: 10.1016/j.jacc.2014.04.089.
 15. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, Wolf PA, Vasani RS. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. *N Engl J Med*. 2004;350:655–663. doi: 10.1056/NEJMoa031994.
 16. Di Angelantonio E, Chowdhury R, Sarwar N, Ray KK, Gobin R, Saleheen D, Thompson A, Gudnason V, Sattar N, Danesh J. B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. *Circulation*. 2009;120:2177–2187. doi: 10.1161/CIRCULATIONAHA.109.884866.
 17. Saunders JT, Nambi V, de Lemos JA, Chambless LE, Virani SS, Boerwinkle E, Hoogeveen RC, Liu X, Astor BC, Mosley TH, Folsom AR, Heiss G, Coresh J, Ballantyne CM. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. *Circulation*. 2011;123:1367–1376. doi: 10.1161/CIRCULATIONAHA.110.005264.
 18. de Lemos JA, Drazner MH, Omland T, Ayers CR, Khera A, Rohatgi A, Hashim I, Berry JD, Das SR, Morrow DA, McGuire DK. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. *JAMA*. 2010;304:2503–2512. doi: 10.1001/jama.2010.1768.
 19. deFilippi CR, de Lemos JA, Christenson RH, Gottdiener JS, Kop WJ, Zhan M, Seliger SL. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. *JAMA*. 2010;304:2494–2502. doi: 10.1001/jama.2010.1708.
 20. Everett BM, Cook NR, Magnone MC, Bobadilla M, Kim E, Rifai N, Ridker PM, Pradhan AD. Sensitive cardiac troponin T assay and the risk of incident cardiovascular disease in women with and without diabetes mellitus: the Women's Health Study. *Circulation*. 2011;123:2811–2818. doi: 10.1161/CIRCULATIONAHA.110.009928.
 21. Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: An individual participant meta-analysis. *Lancet*. 2010;375:132–140.
 22. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, Foster E, Hlatky MA, Hodgson JM, Kushner FG, Lauer MS, Shaw LJ, Smith SC Jr, Taylor AJ, Weintraub WS, Wenger NK, Jacobs AK; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2010;122:e584–e636. doi: 10.1161/CIR.0b013e3182051b4c.
 23. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, Jacques PF, Rifai N, Selhub J, Robins SJ, Benjamin EJ, D'Agostino RB, Vasani RS. Multiple biomarkers for the prediction of first major cardiovascular events and death. *N Engl J Med*. 2006;355:2631–2639. doi: 10.1056/NEJMoa055373.
 24. Zethelius B, Berglund L, Sundström J, Ingelsson E, Basu S, Larsson A, Venge P, Arnlöv J. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. *N Engl J Med*. 2008;358:2107–2116. doi: 10.1056/NEJMoa0707064.
 25. Melander O, Newton-Cheh C, Almgren P, Hedblad B, Berglund G, Engström G, Persson M, Smith JG, Magnusson M, Christensson A, Struck J, Morgenthaler NG, Bergmann A, Pencina MJ, Wang TJ. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. *JAMA*. 2009;302:49–57. doi: 10.1001/jama.2009.943.
 26. Kathiresan S, Melander O, Anevski D, Guiducci C, Burt NP, Roos C, Hirschhorn JN, Berglund G, Hedblad B, Groop L, Altschuler DM, Newton-Cheh C, Orho-Melander M. Polymorphisms associated with cholesterol and risk of cardiovascular events. *N Engl J Med*. 2008;358:1240–1249. doi: 10.1056/NEJMoa0706728.
 27. Blankenberg S, Zeller T, Saarela O, Havulinna AS, Kee F, Tunstall-Pedoe H, Kuulasmaa K, Yarnell J, Schnabel RB, Wild PS, Münzel TF, Lackner KJ, Tiret L, Evans A, Salomaa V; MORGAM Project. Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. *Circulation*. 2010;121:2388–2397. doi: 10.1161/CIRCULATIONAHA.109.901413.
 28. Wang TJ, Wollert KC, Larson MG, Coglianese E, McCabe EL, Cheng S, Ho JE, Fradley MG, Ghorbani A, Xanthakis V, Kempf T, Benjamin EJ, Levy D, Vasani RS, Januzzi JL. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. *Circulation*. 2012;126:1596–1604. doi: 10.1161/CIRCULATIONAHA.112.129437.

29. Wang TJ. Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction. *Circulation*. 2011;123:551–565. doi: 10.1161/CIRCULATIONAHA.109.912568.
30. Kannel WB, Abbott RD. A prognostic comparison of asymptomatic left ventricular hypertrophy and unrecognized myocardial infarction: the Framingham Study. *Am Heart J*. 1986;111:391–397.
31. Desai CS, Ning H, Lloyd-Jones DM. Competing cardiovascular outcomes associated with electrocardiographic left ventricular hypertrophy: the Atherosclerosis Risk in Communities Study. *Heart*. 2012;98:330–334. doi: 10.1136/heartjnl-2011-300819.
32. Chrispin J, Jain A, Soliman EZ, Guallar E, Alonso A, Heckbert SR, Bluemke DA, Lima JA, Nazarian S. Association of electrocardiographic and imaging surrogates of left ventricular hypertrophy with incident atrial fibrillation: MESA (Multi-Ethnic Study of Atherosclerosis). *J Am Coll Cardiol*. 2014;63:2007–2013. doi: 10.1016/j.jacc.2014.01.066.
33. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, Greenland P, Jacob DR Jr, Kronmal R, Liu K, Nelson JC, O'Leary D, Saad MF, Shea S, Szklo M, Tracy RP. Multi-Ethnic Study of Atherosclerosis: objectives and design. *Am J Epidemiol*. 2002;156:871–881.
34. Victor RG, Haley RW, Willett DL, Peshock RM, Vaeth PC, Leonard D, Basit M, Cooper RS, Iannacchione VG, Visscher WA, Staab JM, Hobbs HH; Dallas Heart Study Investigators. The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. *Am J Cardiol*. 2004;93:1473–1480. doi: 10.1016/j.amjcard.2004.02.058.
35. Deo R, Khera A, McGuire DK, Murphy SA, Meo Neto Jde P, Morrow DA, de Lemos JA. Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis. *J Am Coll Cardiol*. 2004;44:1812–1818. doi: 10.1016/j.jacc.2004.07.047.
36. Sokolow M, Lyon TP. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. *Am Heart J*. 1949;37:161–186.
37. Carr JJ, Nelson JC, Wong ND, McNitt-Gray M, Arad Y, Jacobs DR Jr, Sidney S, Bild DE, Williams OD, Detrano RC. Calcified coronary artery plaque measurement with cardiac CT in population-based studies: standardized protocol of Multi-Ethnic Study of Atherosclerosis (MESA) and Coronary Artery Risk Development in Young Adults (CARDIA) study. *Radiology*. 2005;234:35–43. doi: 10.1148/radiol.2341040439.
38. Jain T, Peshock R, McGuire DK, Willett D, Yu Z, Yu Z, Vega GL, Guerra R, Hobbs HH, Grundy SM; Dallas Heart Study Investigators. African Americans and Caucasians have a similar prevalence of coronary calcium in the Dallas Heart Study. *J Am Coll Cardiol*. 2004;44:1011–1017. doi: 10.1016/j.jacc.2004.05.069.
39. de Lemos JA, McGuire DK, Khera A, Das SR, Murphy SA, Omland T, Drazner MH. Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: results from the Dallas Heart Study. *Am Heart J*. 2009;157:746–753. doi: 10.1016/j.ahj.2008.12.017.
40. Lakoski SG, Cushman M, Criqui M, Rundek T, Blumenthal RS, D'Agostino RB Jr, Herrington DM. Gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort. *Am Heart J*. 2006;152:593–598. doi: 10.1016/j.ahj.2006.02.015.
41. Khera A, de Lemos JA, Peshock RM, Lo HS, Stanek HG, Murphy SA, Wians FH Jr, Grundy SM, McGuire DK. Relationship between C-reactive protein and subclinical atherosclerosis: the Dallas Heart Study. *Circulation*. 2006;113:38–43. doi: 10.1161/CIRCULATIONAHA.105.575241.
42. Ndumele CE, Matsushita K, Sang Y, Lazo M, Agarwal SK, Nambi V, Deswal A, Blumenthal RS, Ballantyne CM, Coresh J, Selvin E. N-terminal pro-brain natriuretic peptide and heart failure risk among individuals with and without obesity: the Atherosclerosis Risk in Communities (ARIC) study. *Circulation*. 2016;133:631–638. doi: 10.1161/CIRCULATIONAHA.115.017298.
43. Giannitsis E, Kurz K, Hallermayer K, Jarausch J, Jaffe AS, Katus HA. Analytical validation of a high-sensitivity cardiac troponin T assay. *Clin Chem*. 2010;56:254–261. doi: 10.1373/clinchem.2009.132654.
44. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F; Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. *Circulation*. 2003;107:499–511.
45. Butler J, Kalogeropoulos A, Georgiopoulou V, Belue R, Rodondi N, Garcia M, Bauer DC, Satterfield S, Smith AL, Vaccarino V, Newman AB, Harris TB, Wilson PW, Kritchevsky SB; Health ABC Study. Incident heart failure prediction in the elderly: the health ABC heart failure score. *Circ Heart Fail*. 2008;1:125–133. doi: 10.1161/CIRCHEARTFAILURE.108.768457.
46. Agarwal SK, Chambless LE, Ballantyne CM, Astor B, Bertoni AG, Chang PP, Folsom AR, He M, Hoogeveen RC, Ni H, Quibrera PM, Rosamond WD, Russell SD, Shahar E, Heiss G. Prediction of incident heart failure in general practice: the Atherosclerosis Risk in Communities (ARIC) study. *Circ Heart Fail*. 2012;5:422–429. doi: 10.1161/CIRCHEARTFAILURE.111.964841.
47. Chambless LE, Cummiskey CP, Cui G. Several methods to assess improvement in risk prediction models: extension to survival analysis. *Stat Med*. 2011;30:22–38. doi: 10.1002/sim.4026.
48. Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. *Stat Med*. 2011;30:11–21. doi: 10.1002/sim.4085.
49. Kremers WK. Technical report series no. 80, concordance for survival time data: fixed and time-dependent covariates and possible ties in predictor and time. Rochester, MN: Mayo Clinic College of Medicine; 2007.
50. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW, Eddleman KM, Jarrett NM, LaBresh K, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2014;129(25 Suppl 2):S1–S45. doi: 10.1161/01.cir.0000437738.63853.7a.
51. Yeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS. Population trends in the incidence and outcomes of acute myocardial infarction. *N Engl J Med*. 2010;362:2155–2165. doi: 10.1056/NEJMoa0908610.
52. Nambi V, Liu X, Chambless LE, de Lemos JA, Virani SS, Agarwal S, Boerwinkle E, Hoogeveen RC, Aguilar D, Astor BC, Srinivas PR, Deswal A, Mosley TH, Coresh J, Folsom AR, Heiss G, Ballantyne CM. Troponin T and N-terminal pro-B-type natriuretic peptide: a biomarker approach to predict heart failure risk—the atherosclerosis risk in communities study. *Clin Chem*. 2013;59:1802–1810. doi: 10.1373/clinchem.2013.203638.
53. Huffman MD, Berry JD, Ning H, Dyer AR, Garside DB, Cai X, Daviglus ML, Lloyd-Jones DM. Lifetime risk for heart failure among white and black Americans: cardiovascular lifetime risk pooling

- project. *J Am Coll Cardiol*. 2013;61:1510–1517. doi: 10.1016/j.jacc.2013.01.022.
54. D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. *Circulation*. 2008;117:743–753. doi: 10.1161/CIRCULATIONAHA.107.699579.
55. Kim MH, Johnston SS, Chu BC, Dalal MR, Schulman KL. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. *Circ Cardiovasc Qual Outcomes*. 2011;4:313–320. doi: 10.1161/CIRCOUTCOMES.110.958165.
56. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med*. 2015;373:2117–2128. doi: 10.1056/NEJMoa1504720.
57. Ledwidge M, Gallagher J, Conlon C, Tallon E, O'Connell E, Dawkins I, Watson C, O'Hanlon R, Bermingham M, Patle A, Badabhagn MR, Murtagh G, Voon V, Tilson L, Barry M, McDonald L, Maurer B, McDonald K. Natriuretic peptide-based screening and collaborative care for heart failure: the stop-hf randomized trial. *JAMA*. 2013;310:66–74.